Marc Beer has made a name for himself as a venture capitalist in the world of biotech. Formerly the CEO of Aegerion, Beer is now focusing on women’s health with his new company Renovia Inc., which just secured $32 million in funding.
Based in Boston, Renovia is a biotech startup focusing on diagnosis and treatment for disorders in the pelvic floor. This is a potential customer base of 250 million women all over the world. Leva, their flagship product, got approved by the FDA in April of this year.
With the help of Ascension Ventures from Missouri and New York-based Perceptive Advisers, Beer got the Longwood Fund to help secur tens of millions in investments. The Longwood Fund is seen as the ideal partner in this venture given their evolving interest in the healthcare industry. Now Revoia has the funds it needs to ship four new products, including an update to the Leva.
Beer stated his excitement in a recent statement. Now his company can continue forward in updating the healthcare options made available to millions of women. Having their own technologies and new digital platforms, Beer sees a new era of patients being informed by having an increased understanding of pelvic floor disorders so they can make decisions that best fir their needs. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues
Renovia is Beer’s return to venture capitalism since leaving Aegerion in 2015.
About Marc Beer:
Marc Beer is an American businessman and venture capitalist. He graduated from Miami University in Ohio. He was a founded Good Start Genetics, a genetics screening company, and was a member of the Business Advisory Council. This led to the Mass Life Science Board of the Commonwealth and the Bio (Biotechnology Industry Organization) Emerging Companies Section Governing Board. Jumping deeper into the biotech industry, Beer worked sales and marketing for pharmaceuticals at Abbott Laboratories. Before long Beer went to work as Vice President for Genzyme, a company that is dedicated to diagnosing and treating rare diseases all over the world.
Soon the time came for Beer to try his luck running his own company. He founded ViaCell in 2007, a company that dealt in stem cells from umbilical cords. Seven years later, ViaCell had 300 employees and was bought out by PerkinElmer. While running his own company, Beer also sat on Erytech Pharma’s board of directors. This gave him a diverse set of executive experiences that served him well when he met Yolanda Lorie and Ramon Iglesias, MD. They created Aegerion Pharmaceuticals and launched in 36 countries on a mission to identify and treat rare diseases. After leaving his CEO position, Beer founded Renovia, a company focused solely on addressing pelvic floor dysfunction affecting millions of women around the world by giving them detailed diagnosis reports and personalized findings that will assist in their selection of products and treatment.